Is anyone really shopping for Bristol-Myers?

The pharma would make a poor acquisition for just about anyone. While the failure of Opdivo – its cash cow – was a devastating hit, it didn't exactly cripple the company, or the drug.

By Lisa LaMotta • Feb. 22, 2017

Valeant expands licensing deal for combo eye product

The drugmaker sees Bausch & Lomb as a source of strength, even as the drugmaker sells off other assets to keep up with debt payments. 

By Judy Packer-Tursman • Feb. 22, 2017

Bristol caves to investor pressure

The big pharma is making changes to its board of directors amid takeout speculation. 

By Lisa LaMotta • Feb. 21, 2017

Takeda preps to split off consumer health biz

After a year, Takeda reveals more details of its consumer healthcare business spinout planned for April. 

By Suzanne Elvidge • Feb. 20, 2017

AstraZeneca's selling spree continues with Zoladex

Privately-owned TerSera Therapeutics aims to take Zoladex forward in North America after paying the British pharma $250 million upfront

By Suzanne Elvidge • Feb. 20, 2017

Young startup snags Gilead addiction drug

Palo Alto biotech Amygdala Neurosciences in-licenses an addiction drug from the big biotech. 

By Suzanne Elvidge • Feb. 17, 2017

Prescribed Reading: Sage CEO embellishes, Merck stumbles

Plus, Valeant gets an approval, but is still in a tight spot; Allergan continues its deal spree; and PhRMA tries to deal with image issues. 

By Lisa LaMotta • Feb. 17, 2017

Quotient buys QS Pharma, expanding US footprint

QS Pharma is Quotients’s second U.S. acquisition in the past eight days, following right on the heels of its purchase of Florida-based SeaView Research.

By Judy Packer-Tursman • Feb. 16, 2017

Activist investor moves to block Immunomedics deal

VenBio Select Advisor has accused Immunomedics of selling off rights to its lead cancer drug at a bargain. 

By Suzanne Elvidge • Feb. 16, 2017

Bristol's Caforio open to deals, but soft on pricing

The big pharma chief executive talked pricing, immuno-oncology and M&A at this week's BIO CEO conference in New York. 

By Lisa LaMotta • Feb. 15, 2017

Agenus cuts down Incyte deal for $80M cash in hand

Incyte will accelerate some clinical milestone payments and invest $60 million in Agenus stock under the amended deal. 

By Suzanne Elvidge • Feb. 15, 2017

Sanofi sells off OTC products to Ipsen

The divestiture will help Sanofi meet requirements set by the E.U. in exchange for approval of last year's asset swap with Boehringer Ingelheim. 

By Suzanne Elvidge • Feb. 14, 2017

Allergan builds out aesthetics business with $2.5B deal

The Botox developer said the new acquisition should strengthen its medical aesthetics business, which helped the company report strong earnings during Q4.

By Jacob Bell • Feb. 13, 2017

Seattle Genetics grabs rights to Immunomedics' tumor drug

The West Coast biotech put up $250 million to license Immunomedics therapy, with milestone payments pushing total deal value potentially as high as $2 billion. 

By Jacob Bell • Feb. 10, 2017

Prescribed Reading: When will Gilead tap its cash hoard?

2017 looks bleak for Gilead's hepatitis C business, Lundbeck reports yet another Alzheimer's trial failure and a new pricing controversy bubbles up. 

By Lisa LaMotta • Feb. 10, 2017

Neurocrine enters licensing deal for Parkinson's drug

The company has agreed to pay Portuguese drugmaker Bial $30 million upfront for access to Ongentys, which gained approval in Europe last summer.

By Jacob Bell • Feb. 10, 2017

Ovid looks to biomarkers in new rare disease deal

A collaboration with NeuroPointDX could help Ovid in its development of a treatment for the genetic disorder Angelman syndrome.

By Suzanne Elvidge • Feb. 10, 2017

Renova inks deal with Janssen for IND file

The deal with Janssen should help boost the San Diego-based biotech's work in heart failure.

By Suzanne Elvidge • Feb. 8, 2017

Biotech IPOs off to better start in 2017

Rebound from a weaker 2016 performance, plus a newly minted Trump administration and investor optimism should support a more robust IPO market in 2017, but doubts remain.

By Jacob Bell • Feb. 3, 2017

Astellas inks biomarker deal to pinpoint Xtandi patients

GenomeDx Biosciences' genome profiling tech will help identify the patients who are most likely to respond to Astellas' drug.

By Suzanne Elvidge • Feb. 3, 2017

Cytokinetics pulls in Royalty Pharma to secure $100M

The late-stage biotech says the deal will give it needed cash to pump into a Phase 3 trial of its heart failure drug candidate.

By Judy Packer-Tursman • Feb. 2, 2017

Novo Nordisk plans $145M investment in new UK research center

Amid the uncertainty of Brexit, Novo Nordisk's partnership with the University of Oxford is a dose of good news for British science.

By Suzanne Elvidge • Feb. 2, 2017

Biogen nixes licensing deal for autoimmune drug

The Cambridge biotech had paid Mitsubishi Tanabe $60 million to gain access to the drug a year and a half ago, but hopes for a Gilenya competitor didn't pan out. 

By Judy Packer-Tursman • Feb. 1, 2017

Takeda bolsters cancer pipeline with Exelixis deal

The Japanese pharma already kicked off 2017 with a $5.2 billion deal for Ariad Pharma and its blood cancer drug — part of a broader effort to build out a more competitive portfolio in oncology. 

By Suzanne Elvidge • Feb. 1, 2017

Mallinckrodt unloads spinal drug unit

The deal, worth up to $357 million, continues the U.K.-based biopharma's work to refine its specialty drug pipeline.

By Jacob Bell • Jan. 31, 2017